EGFR-TKIs-话题@MedSci

#EGFR-TKIs#

12篇内容 | 1272人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2216482, encodeId=9b412216482f6, content=<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a> <a href='/topic/show?id=7ed165e3b6' target=_blank style='color:#2F92EE;'>#EGFR-TKIs#</a> <a href='/topic/show?id=7bbf11e031f1' target=_blank style='color:#2F92EE;'>#EGFR基因共突变#</a>, objectTitle=罗详冲：EGFR基因共突变晚期 NSCLC 患者一线治疗策略最全总结, objectType=article, longId=835895, objectId=f39483589581, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240714/1720950459912_5579292.jpg, objectUrl=/article/show_article.do?id=f39483589581, replyNumber=0, likeNumber=92, createdTime=2024-07-23, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=f39483589581, moduleTitle=罗详冲：EGFR基因共突变晚期 NSCLC 患者一线治疗策略最全总结, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f39483589581)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2198262, encodeId=5dc8219826297, content=<a href='/topic/show?id=40875986ec9' target=_blank style='color:#2F92EE;'>#晚期肺腺癌#</a> <a href='/topic/show?id=7ed165e3b6' target=_blank style='color:#2F92EE;'>#EGFR-TKIs#</a> <a href='/topic/show?id=95296e12244' target=_blank style='color:#2F92EE;'>#烟酰胺#</a>, objectTitle=CLIN CANCER RES | 烟酰胺联合EGFR-TKIs治疗EGFR突变晚期肺腺癌, objectType=article, longId=821388, objectId=39af821388e2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240412/1712926536653_6145188.jpg, objectUrl=/article/show_article.do?id=39af821388e2, replyNumber=0, likeNumber=90, createdTime=2024-04-13, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=39af821388e2, moduleTitle=CLIN CANCER RES | 烟酰胺联合EGFR-TKIs治疗EGFR突变晚期肺腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39af821388e2)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2196113, encodeId=e0b5219611324, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=a11611291471' target=_blank style='color:#2F92EE;'>#EGFR T790M突变#</a> <a href='/topic/show?id=7ed165e3b6' target=_blank style='color:#2F92EE;'>#EGFR-TKIs#</a>, objectTitle=原发性与获得性EGFR T790M突变非小细胞肺癌患者的临床特征和预后差异, objectType=article, longId=818527, objectId=8ccb81852ea0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-is-working-at-the-hospital-P9JMZYE.jpg, objectUrl=/article/show_article.do?id=8ccb81852ea0, replyNumber=0, likeNumber=125, createdTime=2024-03-29, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=8ccb81852ea0, moduleTitle=原发性与获得性EGFR T790M突变非小细胞肺癌患者的临床特征和预后差异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ccb81852ea0)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2188763, encodeId=c8092188e637b, content=<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a> <a href='/topic/show?id=7ed165e3b6' target=_blank style='color:#2F92EE;'>#EGFR-TKIs#</a> <a href='/topic/show?id=b0054454337' target=_blank style='color:#2F92EE;'>#奥希替尼#</a>, objectTitle=晚期NSCLC奥希替尼耐药咋应对？从联合策略到第四代EGFR-TKIs, objectType=article, longId=814267, objectId=b1ca81426e76, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-conference-P42ZDP5.jpg, objectUrl=/article/show_article.do?id=b1ca81426e76, replyNumber=0, likeNumber=98, createdTime=2024-02-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b1ca81426e76, moduleTitle=晚期NSCLC奥希替尼耐药咋应对？从联合策略到第四代EGFR-TKIs, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1ca81426e76)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1940484, encodeId=9d9b19404840e, content=<a href='/topic/show?id=7ed165e3b6' target=_blank style='color:#2F92EE;'>#EGFR-TKIs#</a>, objectTitle=Oncologist：全球多中心真实世界探索EGFR-TKIs治疗罕见EGFR突变NSCLC患者的疗效, objectType=article, longId=300760, objectId=f451300e604a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f451300e604a, replyNumber=0, likeNumber=88, createdTime=2022-07-23, rootId=0, userName=hbwxf, userId=55ce62, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f451300e604a, moduleTitle=Oncologist：全球多中心真实世界探索EGFR-TKIs治疗罕见EGFR突变NSCLC患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f451300e604a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940482, encodeId=5c2b194048295, content=<a href='/topic/show?id=7ed165e3b6' target=_blank style='color:#2F92EE;'>#EGFR-TKIs#</a>, objectTitle=Thorac Cancer：EGFR突变肺癌EGFR-TKIs治疗进展后应用免疫检查点抑制剂治疗的疗效, objectType=article, longId=291958, objectId=864c29195801, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=864c29195801, replyNumber=0, likeNumber=98, createdTime=2022-09-03, rootId=0, userName=hbwxf, userId=55ce62, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=864c29195801, moduleTitle=Thorac Cancer：EGFR突变肺癌EGFR-TKIs治疗进展后应用免疫检查点抑制剂治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=864c29195801)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940481, encodeId=2013194048183, content=<a href='/topic/show?id=7ed165e3b6' target=_blank style='color:#2F92EE;'>#EGFR-TKIs#</a>, objectTitle=Thorac Cancer： EGFR-TKIs提前应用可改善不可切除的III期EGFR突变肺腺癌的预后, objectType=article, longId=220997, objectId=b57822099e0a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b57822099e0a, replyNumber=0, likeNumber=0, createdTime=2022-11-08, rootId=0, userName=hbwxf, userId=55ce62, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b57822099e0a, moduleTitle=Thorac Cancer： EGFR-TKIs提前应用可改善不可切除的III期EGFR突变肺腺癌的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b57822099e0a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940479, encodeId=c50419404e926, content=<a href='/topic/show?id=7ed165e3b6' target=_blank style='color:#2F92EE;'>#EGFR-TKIs#</a>, objectTitle=Front Oncol： EGFR-TKIs新辅助治疗可手术切除NSCLC患者的疗效和安全性, objectType=article, longId=218184, objectId=5824218184a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5824218184a3, replyNumber=0, likeNumber=101, createdTime=2022-09-14, rootId=0, userName=hbwxf, userId=55ce62, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5824218184a3, moduleTitle=Front Oncol： EGFR-TKIs新辅助治疗可手术切除NSCLC患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5824218184a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940480, encodeId=575b1940480bb, content=<a href='/topic/show?id=7ed165e3b6' target=_blank style='color:#2F92EE;'>#EGFR-TKIs#</a>, objectTitle=解毒复正汤联合EGFR-TKIs对老年晚期肺癌患者的临床疗效观察, objectType=article, longId=220637, objectId=011e22063e38, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=011e22063e38, replyNumber=0, likeNumber=71, createdTime=2022-04-30, rootId=0, userName=hbwxf, userId=55ce62, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=011e22063e38, moduleTitle=解毒复正汤联合EGFR-TKIs对老年晚期肺癌患者的临床疗效观察, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=011e22063e38)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940483, encodeId=a11119404834b, content=<a href='/topic/show?id=7ed165e3b6' target=_blank style='color:#2F92EE;'>#EGFR-TKIs#</a>, objectTitle=Transl Lung Cancer Res: 广医一院团队：第一代EGFR-TKIs(吉非替尼、厄洛替尼和埃克替尼)术后辅助治疗NSCLC伴有EGFR敏感突变患者的疗效比较, objectType=article, longId=295260, objectId=94052952604f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94052952604f, replyNumber=0, likeNumber=76, createdTime=2022-04-24, rootId=0, userName=hbwxf, userId=55ce62, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94052952604f, moduleTitle=Transl Lung Cancer Res: 广医一院团队：第一代EGFR-TKIs(吉非替尼、厄洛替尼和埃克替尼)术后辅助治疗NSCLC伴有EGFR敏感突变患者的疗效比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94052952604f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940478, encodeId=1f4019404e870, content=<a href='/topic/show?id=7ed165e3b6' target=_blank style='color:#2F92EE;'>#EGFR-TKIs#</a>, objectTitle=EGFR-TKIs药物相关口腔炎病例报告, objectType=article, longId=195842, objectId=3250195842c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3250195842c6, replyNumber=0, likeNumber=91, createdTime=2020-10-11, rootId=0, userName=hbwxf, userId=55ce62, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3250195842c6, moduleTitle=EGFR-TKIs药物相关口腔炎病例报告, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3250195842c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940477, encodeId=5d9119404e753, content=<a href='/topic/show?id=7ed165e3b6' target=_blank style='color:#2F92EE;'>#EGFR-TKIs#</a>, objectTitle=Sci Rep：EGFR-TKIs治疗EGFR突变型非小细胞肺癌的神经生长因子表达及其临床意义, objectType=article, longId=185036, objectId=79b218503619, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=79b218503619, replyNumber=0, likeNumber=95, createdTime=2020-10-09, rootId=0, userName=hbwxf, userId=55ce62, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=79b218503619, moduleTitle=Sci Rep：EGFR-TKIs治疗EGFR突变型非小细胞肺癌的神经生长因子表达及其临床意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=79b218503619)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940476, encodeId=b39719404e6c5, content=<a href='/topic/show?id=7ed165e3b6' target=_blank style='color:#2F92EE;'>#EGFR-TKIs#</a>, objectTitle=JAMA Oncol：EGFR-TKIs治疗联合二甲双胍可明显改善晚期肺腺癌患者的PFS, objectType=article, longId=183104, objectId=0beb18310413, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0beb18310413, replyNumber=0, likeNumber=87, createdTime=2020-10-14, rootId=0, userName=hbwxf, userId=55ce62, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0beb18310413, moduleTitle=JAMA Oncol：EGFR-TKIs治疗联合二甲双胍可明显改善晚期肺腺癌患者的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0beb18310413)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940475, encodeId=6f8c19404e5fa, content=<a href='/topic/show?id=7ed165e3b6' target=_blank style='color:#2F92EE;'>#EGFR-TKIs#</a>, objectTitle=JAMA Oncol：共存突变可影响 EGFR-TKIs的疗效, objectType=article, longId=134084, objectId=2a11134084c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a11134084c4, replyNumber=0, likeNumber=77, createdTime=2018-10-19, rootId=0, userName=hbwxf, userId=55ce62, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a11134084c4, moduleTitle=JAMA Oncol：共存突变可影响 EGFR-TKIs的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a11134084c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940474, encodeId=a03a19404e420, content=<a href='/topic/show?id=7ed165e3b6' target=_blank style='color:#2F92EE;'>#EGFR-TKIs#</a>, objectTitle=Eur Respir J：EGFR-wt晚期非小细胞肺癌：EGFR-TKIs疗效不如化疗？, objectType=article, longId=114074, objectId=7e4c1140e4f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e4c1140e4f6, replyNumber=0, likeNumber=89, createdTime=2018-02-23, rootId=0, userName=hbwxf, userId=55ce62, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e4c1140e4f6, moduleTitle=Eur Respir J：EGFR-wt晚期非小细胞肺癌：EGFR-TKIs疗效不如化疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e4c1140e4f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940473, encodeId=038f19404e324, content=<a href='/topic/show?id=7ed165e3b6' target=_blank style='color:#2F92EE;'>#EGFR-TKIs#</a>, objectTitle=Oncologist：阿法替尼治疗EGFR-TKIs获益的非小细胞肺癌患者进展后的经验分析, objectType=article, longId=42035, objectId=067d42035e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=067d42035e9, replyNumber=0, likeNumber=82, createdTime=2015-10-06, rootId=0, userName=hbwxf, userId=55ce62, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=067d42035e9, moduleTitle=Oncologist：阿法替尼治疗EGFR-TKIs获益的非小细胞肺癌患者进展后的经验分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=067d42035e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

EGFR-TKIs

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#NSCLC# #EGFR-TKIs# #EGFR基因共突变#

罗详冲：EGFR基因共突变晚期 NSCLC 患者一线治疗策略最全总结

2024-07-23发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#晚期肺腺癌# #EGFR-TKIs# #烟酰胺#

CLIN CANCER RES | 烟酰胺联合EGFR-TKIs治疗EGFR突变晚期肺腺癌

2024-04-13发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #EGFR T790M突变# #EGFR-TKIs#

原发性与获得性EGFR T790M突变非小细胞肺癌患者的临床特征和预后差异

2024-03-29发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#NSCLC# #EGFR-TKIs# #奥希替尼#

晚期NSCLC奥希替尼耐药咋应对？从联合策略到第四代EGFR-TKIs

2024-02-22发表于上海

hbwxf (审核中...)

前往app查看评论内容

#EGFR-TKIs#

Oncologist：全球多中心真实世界探索EGFR-TKIs治疗罕见EGFR突变NSCLC患者的疗效

2022-07-23

hbwxf (审核中...)

前往app查看评论内容

#EGFR-TKIs#

Thorac Cancer：EGFR突变肺癌EGFR-TKIs治疗进展后应用免疫检查点抑制剂治疗的疗效

2022-09-03

hbwxf (审核中...)

前往app查看评论内容

#EGFR-TKIs#

Thorac Cancer： EGFR-TKIs提前应用可改善不可切除的III期EGFR突变肺腺癌的预后

2022-11-08

hbwxf (审核中...)

前往app查看评论内容

#EGFR-TKIs#

Front Oncol： EGFR-TKIs新辅助治疗可手术切除NSCLC患者的疗效和安全性

2022-09-14

hbwxf (审核中...)

前往app查看评论内容

#EGFR-TKIs#

解毒复正汤联合EGFR-TKIs对老年晚期肺癌患者的临床疗效观察

2022-04-30

hbwxf (审核中...)

前往app查看评论内容

#EGFR-TKIs#

Transl Lung Cancer Res: 广医一院团队：第一代EGFR-TKIs(吉非替尼、厄洛替尼和埃克替尼)术后辅助治疗NSCLC伴有EGFR敏感突变患者的疗效比较

2022-04-24

hbwxf (审核中...)

前往app查看评论内容

#EGFR-TKIs#

EGFR-TKIs药物相关口腔炎病例报告

2020-10-11

hbwxf (审核中...)

前往app查看评论内容

#EGFR-TKIs#

Sci Rep：EGFR-TKIs治疗EGFR突变型非小细胞肺癌的神经生长因子表达及其临床意义

2020-10-09

hbwxf (审核中...)

前往app查看评论内容

#EGFR-TKIs#

JAMA Oncol：EGFR-TKIs治疗联合二甲双胍可明显改善晚期肺腺癌患者的PFS

2020-10-14

hbwxf (审核中...)

前往app查看评论内容

#EGFR-TKIs#

JAMA Oncol：共存突变可影响 EGFR-TKIs的疗效

2018-10-19

hbwxf (审核中...)

前往app查看评论内容

#EGFR-TKIs#

Eur Respir J：EGFR-wt晚期非小细胞肺癌：EGFR-TKIs疗效不如化疗？

2018-02-23

hbwxf (审核中...)

前往app查看评论内容

#EGFR-TKIs#

Oncologist：阿法替尼治疗EGFR-TKIs获益的非小细胞肺癌患者进展后的经验分析

2015-10-06

科室
- - 订阅+
  - 更多科室
工具
服务